CLINICAL TRIALS PROFILE FOR EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

All Clinical Trials for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00799864 ↗	A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years	Recruiting	Janssen Sciences Ireland UC	Phase 2	2011-01-07	The purpose of this study is to evaluate the pharmacokinetics, safety and antiviral activity of rilpivirine (TMC278) 25 milligram (mg) or adjusted dose once daily in combination with an investigator-selected background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs) (zidovudine [AZT], abacavir [ABC], or tenofovir disoproxil fumarate [TDF] in combination with lamivudine [3TC] or emtricitabine [FTC] in antiretroviral (ARV) treatment-naïve adolescents and children aged greater than or equal to (>=) 6 to less than (
NCT01252940 ↗	Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF	Completed	Gilead Sciences	Phase 3	2010-11-01	The purpose of this randomized, open-label, multicenter, active-controlled Phase 3b study is to evaluate the noninferiority of the emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) single-tablet regimen (STR; also referred to as fixed-dose regimen or fixed-dose tablet) relative to regimens consisting of a ritonavir-boosted protease inhibitor (PI+RTV) and two nucleoside reverse transcriptase inhibitors (NRTIs) in virologically suppressed, HIV-1 infected subjects. The FTC/RPV/TDF STR could offer an attractive treatment option to patients who wish to simplify dosing by reducing pill burden or to improve the tolerability of their treatment. Participants will be randomized into 2 groups, the FTC/RPV/TDF STR group, in which participants will switch treatment regimens at the start of the study, and the Stay on Baseline Regimen (SBR)/Delayed Switch group, in which participants will remain on their baseline regimen during the first 24 weeks of the study (designed to provide an initial active control), and may switch to the FTC/RPV/TDF STR at the Week 24 visit. After the 48-week study analysis period, participants may continue to receive the FTC/RPV/TDF STR per protocol before switching to a commercially available source.
NCT01286740 ↗	Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR	Completed	Gilead Sciences	Phase 2	2011-01-01	The purpose of this Phase 2b study was to evaluate the efficacy and safety of the emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR, after switching from the efavirenz (EFV)/FTC/TDF STR at baseline, in maintaining HIV-1 RNA < 50 copies/mL at Week 12. HIV-infected patients were enrolled if they had received EFV/FTC/TDF for ≥ 3 months prior to study start, were experiencing safety or tolerability concerns (in particular, EFV-related intolerance), and wished to change to an alternate, better-tolerated regimen.
NCT01309243 ↗	Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiret	Completed	Gilead Sciences	Phase 3	2011-02-01	The purpose of the study was to evaluate the safety and efficacy of the emtricitabine (FTC)/rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF) single-tablet regimen (STR) compared with the efavirenz (EFV)/FTC/TDF STR in HIV-1 infected adults who had not previously received treatment with antiretroviral medications. Participants were randomized in a 1:1 ratio to receive one of the study treatments. Randomization was stratified by HIV-1 RNA level (≤ 100,000 copies/mL or > 100,000 copies/mL) at screening. A treatment duration of 96 weeks was planned, with the option for subjects in FTC/RPV/TDF STR arm to receive treatment following the Week 96 visit until FTC/RPV/TDF STR is commercially available or until Gilead Sciences elects to terminate development in that country.
NCT01500616 ↗	Telaprevir Open-Label Study in Co-Infected Patients	Completed	Janssen-Cilag International NV	Phase 3	2012-06-01	The purpose of this study is to collect safety and tolerability data on telaprevir treatment in combination with Peg-IFN-alfa and RBV in patients with HIV/genotype 1 chronic HCV coinfection with severe fibrosis or compensated cirrhosis who are not eligible for enrollment into an ongoing clinical study of telaprevir.
NCT01709084 ↗	A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment	Completed	Janssen-Cilag International NV	Phase 3	2013-10-02	The purpose of this study is to demonstrate noninferiority (a new treatment is equivalent to standard treatment) in terms of the percentage of patients who have plasma human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid (RNA) levels less than 400 copies per mL after 48 weeks of randomized treatment with tenofovir disoproxil fumarate/emtricitabine/rilpivirine (TDF/FTC/RPV) versus TDF/FTC/efavirenz (TDF/FTC/EFV).
NCT01777997 ↗	FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4	2013-04-25	This study was done with people who were infected with HIV, but did not show any signs of having HIV. They were also feeling well without taking HIV medication and had low or undetectable levels of the virus in the blood. The purpose of this study was to see if taking HIV medication (antiretroviral therapy [ART]) would reduce immune activation (a signal that the body is fighting an infection) in people who have HIV, but did not show symptoms. Also this study helped determine how safe the drug was and how well people reacted to the drug. For this study, the following antiretroviral therapy (ART) was be provided in the form of a single tablet that contains three different drugs: emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF). These drugs were combined as one tablet which was approved by the Food and Drug Administration (FDA) as a single pill to treat HIV infection. The HIV medication provided was one of the recommended treatments for HIV, including people with low viral loads (how much HIV you have in your body) who were taking HIV drugs for the first time. The risks seen with this HIV medication were the same that one would encounter when taking these drugs outside of the study.

Clinical Trial Conditions for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Condition Name

Condition Name for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Intervention	Trials
HIV-1 Infection	7
Healthy	1
Hepatitis C, Chronic	1
HIV-1	1

Condition MeSH

Condition MeSH for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Intervention	Trials
Immunologic Deficiency Syndromes	2
HIV Infections	1
Acquired Immunodeficiency Syndrome	1
Hepatitis C, Chronic	1

Clinical Trial Locations for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Trials by Country

Trials by Country for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Location	Trials
United States	130
Canada	16
Germany	7
United Kingdom	6
Belgium	5

Trials by US State

Trials by US State for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Location	Trials
Texas	7
Missouri	7
District of Columbia	7
California	7
Massachusetts	6

Clinical Trial Progress for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Clinical Trial Phase

Clinical Trial Phase for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	6
Phase 2	2

Clinical Trial Status

Clinical Trial Status for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Clinical Trial Phase	Trials
Completed	10
Recruiting	1

Clinical Trial Sponsors for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Sponsor Name

Sponsor Name for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Sponsor	Trials
Gilead Sciences	6
Janssen-Cilag International NV	2
National Institute of Allergy and Infectious Diseases (NIAID)	1

Sponsor Type

Sponsor Type for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Sponsor	Trials
Industry	10
Other	2
NIH	1

Last updated: April 29, 2026

Emtricitabine / Rilpivirine Hydrochloride / Tenofovir Disoproxil Fumarate (FTC/RPV/TDF): Clinical Trials Update, Market Analysis, and 2026-2031 Projection

What is the product and what are the practical clinical-trial implications?

The combination emtricitabine (FTC) / rilpivirine hydrochloride (RPV) / tenofovir disoproxil fumarate (TDF) is used as an oral antiretroviral therapy in people with HIV-1. As a fixed-dose triple regimen, its clinical value is anchored in two properties that shape trial conduct and endpoints:

• Core efficacy from FTC (NRTI) + TDF (NRTI) with RPV (NNRTI).
• Established comparator landscape, which tends to drive late-stage programs toward equivalence, switching, formulation, and long-term safety rather than novel efficacy claims.

Given that FTC/RPV/TDF components and the regimen class are well established, trial “updates” for this specific combination are typically driven by:

• Switching studies (maintained viral suppression when moving from another regimen).
• Long-term safety and tolerability follow-up.
• Real-world confirmatory evidence and pharmacokinetic bridging for label expansions (where applicable).

No new, program-defining Phase 3 efficacy trials for FTC/RPV/TDF are consistently visible as “new entrants” in the trial pipeline relative to the breadth of ongoing HIV regimen comparisons across the wider NNRTI and NRTI landscape. Instead, the dominant pattern is incremental evidence that supports continued use under existing guidelines and addresses tolerability, resistance monitoring, and adherence.

What is the clinical trial activity pattern for FTC/RPV/TDF?

Across HIV regimen development, clinical trial updates for an established fixed-dose combination typically come from these buckets:

Trial bucket	What it tests	Typical enrollment profile	What it changes commercially
Switch studies	Virologic suppression after switching to FTC/RPV/TDF	Patients suppressed on prior ART	Supports formulary adoption and persistence
Long-term safety	Kidney, bone, neuropsychiatric, hepatic events; lipids	Multi-year follow-up cohorts	Supports risk-benefit narratives in guidelines
PK/bioavailability	Exposure consistency, food effect, population covariates	Healthy volunteers or stable HIV populations	Enables label refinement and reduces switching friction
Resistance-focused analyses	Outcomes by baseline viral load and resistance-associated substitutions	Virologically suppressed or near-suppressed cohorts	Impacts uptake rules (e.g., suitability criteria)

Commercial implication: In established triple-drug fixed-dose regimens, the highest-impact updates are those that remove use constraints (food requirements, baseline viral load cutoffs, prior therapy eligibility) or that show non-inferior effectiveness in broader switching populations. If evidence tightens restrictions (commonly tied to baseline viral load and resistance risk), it can slow uptake even with proven efficacy.

---

How big is the market for FTC/RPV/TDF and what is the direction of travel?

What drives demand for this regimen class?

Demand is driven by:

• Chronic therapy adoption: HIV is lifelong, so regimen share shifts through prescribing preferences, payer incentives, and guideline alignment.
• Switching behavior: Once patients are suppressed, clinicians consider fixed-dose simplicity, tolerability, and pill burden.
• Competition from newer backbones: TAF (tenofovir alafenamide) strategies, integrase-based regimens, and newer NNRTI-based options increasingly pressure TDF-containing combinations.

Where does FTC/RPV/TDF sit in the competitive set?

FTC/RPV/TDF competes against:

• Integrase inhibitor-based single-tablet regimens (major share gravity in many geographies).
• TAF-based NRTI backbones that can present a better renal and bone safety profile than TDF in many settings.
• Other NNRTI-based fixed-dose options, where RPV retains positioning in patients eligible for NNRTI use.

Commercial implication: The regimen’s growth ceiling tends to be capped by the shift toward integrase-based regimens and TAF backbones, while it can still hold share where NNRTI use is guideline-supported and where switching simplicity and tolerability are valued.

---

2026-2031 Market Projection

What is the projection logic and growth profile?

A defensible projection for FTC/RPV/TDF is based on:

• Volume stickiness from chronic use and switching inertia.
• Share dilution from integrase- and TAF-led competitive pressure.
• Patent status and generic competition in major markets (TDF, FTC, and RPV act as well-established molecules with broad generic availability in many jurisdictions, reducing pricing power for fixed-dose products and limiting incremental revenue growth).

Resulting profile (directional, product-level):

• Revenue growth is constrained by pricing pressure and generic penetration.
• Unit volumes likely remain stable to modestly declining in mature markets, with slower erosion in geographies where regimen cost and formulary structure preserve older fixed-dose options.

Projected 2026-2031 (index-based)

Because pricing and market sizing require granular country-by-country data, the projection below expresses growth as an index that reflects relative change under typical HIV market dynamics (stable units, pressured pricing).

Year	Revenue index (2025=100)	Unit index (2025=100)	Interpretation
2025	100	100	Baseline anchored to mature-market dynamics
2026	98	100	Pricing pressure offsets stable usage
2027	96	99	Minor unit erosion from regimen preference shifts
2028	94	98	Ongoing integrase and TAF substitution
2029	92	97	Continued share dilution
2030	90	96	Formulary tightening in higher-income markets
2031	88	95	Net decline reflects competitive gravity and generics

Net view: Over a 6-year span, the regimen’s revenue declines modestly in real business terms (units down slightly; price down faster). Upside scenarios require new label expansions or payer-driven reversals, which is not the typical pattern for established NNRTI/TDF fixed-dose combinations.

---

What do label and prescribing constraints imply for uptake?

Which clinical factors usually govern eligibility for RPV-containing regimens?

In practice, RPV-containing regimens are sensitive to:

• Baseline viral load thresholds (commonly used to steer prescribing).
• Resistance patterns (NNRTI-associated substitutions).
• Drug interaction profile and absorption conditions (notably acid-reducing agents affecting RPV).

Even when the regimen is effective in eligible patients, these constraints shape uptake. In competitive environments, integrase inhibitor regimens tend to win when they offer fewer practical restrictions.

---

Key business takeaways

What matters most for investment or R&D decisions?

• This regimen is mature: clinical updates are usually incremental (switching, long-term safety, PK) rather than new efficacy breakthroughs.
• Commercial growth is structurally capped by generic penetration, pricing pressure, and substitution toward integrase-based and TAF-based options.
• Uptake depends on eligibility rules for RPV (viral load suitability, resistance, and absorption/drug interaction constraints), which can limit share expansion even when efficacy is maintained.
• Forecast direction is mild decline: revenue softens faster than units; unit volumes erode slowly in mature markets.

---

FAQs

1) Is FTC/RPV/TDF still relevant in clinical practice?

Yes. It remains used where prescribing guidance supports NNRTI-based fixed-dose options and where patients meet eligibility criteria tied to RPV exposure and resistance risk.

2) What is the main competitive threat to this regimen?

Integrase inhibitor-based single-tablet regimens and TAF-backed strategies that can improve renal and bone risk profiles and broaden eligibility.

3) What type of clinical evidence would materially change market share?

Trials that demonstrate maintained virologic suppression with expanded eligibility (including broader baseline viral load ranges), simplified safety management, or label changes that reduce practical constraints on RPV use.

4) How do generics affect projections?

Generics typically cap pricing and reduce revenue growth even if treated populations remain stable, driving the forecast toward modest revenue decline.

5) What endpoints matter most for switching and long-term studies?

Virologic suppression maintenance, resistance outcomes, adherence-related discontinuations, and long-term safety signals relevant to NRTI exposure (renal and bone for TDF).

---

References

[1] Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. U.S. Department of Health and Human Services.
[2] FDA. Product information and prescribing information for emtricitabine, rilpivirine, and tenofovir disoproxil fumarate-containing regimens.
[3] EACS. European AIDS Clinical Society Guidelines.
[4] WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery.